12.63

0.94% -0.101

Pliant Therapeutics Inc (PLRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$12.73

Offen:

$12.81

24-Stunden-Volumen:

44,124

Relative Volume:

0.12

Marktkapitalisierung:

$766.15M

Einnahmen:

$5.03M

Nettoeinkommen (Verlust:

$-185.41M

KGV:

-4.6091

EPS:

-2.74

Netto-Cashflow:

$-139.79M

1W Leistung:

-1.87%

1M Leistung:

-13.98%

6M Leistung:

-13.57%

1J Leistung:

-10.82%

1-Tages-Spanne:

$12.52

$12.91

1-Wochen-Bereich:

$11.76

$12.94

52-Wochen-Spanne:

$10.22

$19.62

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Firmenname

Pliant Therapeutics Inc

Sektor

Healthcare (1195)

Branche

Biotechnology (683)

Telefon

650-481-6770

Adresse

331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA

Mitarbeiter

166

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

PLRX's Discussions on Twitter

Vergleichen Sie PLRX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PLRX	12.56	766.15M	5.03M	-185.41M	-139.79M	-2.74
VRTX	446.48	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	740.49	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.15	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.56	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.47	24.49B	3.30B	-501.07M	1.03B	11.54

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-05-18	Eingeleitet	Canaccord Genuity	Buy
2023-04-13	Eingeleitet	Robert W. Baird	Outperform
2022-12-14	Eingeleitet	Stifel	Buy
2022-12-07	Eingeleitet	JP Morgan	Overweight
2022-09-01	Eingeleitet	Citigroup	Buy
2022-07-20	Eingeleitet	SVB Leerink	Outperform
2022-05-25	Eingeleitet	Cantor Fitzgerald	Overweight
2021-12-10	Eingeleitet	Oppenheimer	Outperform
2021-11-24	Eingeleitet	RBC Capital Mkts	Outperform
2021-11-03	Eingeleitet	H.C. Wainwright	Buy
2021-04-20	Eingeleitet	BTIG Research	Buy
2021-04-05	Eingeleitet	Citigroup	Buy
2020-06-29	Eingeleitet	Citigroup	Buy
2020-06-29	Eingeleitet	Cowen	Outperform
2020-06-29	Eingeleitet	Needham	Buy
2020-06-29	Eingeleitet	Piper Sandler	Overweight

Alle ansehen

Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten

08:29 AM

Pliant Therapeutics to Participate in Upcoming Investor Events - The Manila Times

08:29 AM

08:00 AM

Pliant Therapeutics to Present at 4 Major Healthcare Conferences in December | PLRX Stock News - StockTitan

08:00 AM

Nov 18, 2024

Pliant Therapeutics Reports Increased Losses and Strategic Focus - TipRanks

Nov 18, 2024

Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024 - GlobeNewswire

Nov 18, 2024

Pliant's Bexotegrast Shows Strong Phase 2 Results in Liver Disease Treatment Trial | PLRX Stock News - StockTitan

Nov 18, 2024

Nov 15, 2024

Redmile Group, LLC Adjusts Stake in Pliant Therapeutics Inc - GuruFocus.com

Nov 15, 2024

First Light Asset Management's Strategic Reduction in Pliant The - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Objective long/short (PLRX) Report - Stock Traders Daily

Nov 14, 2024

Nov 11, 2024

Pliant Therapeutics maintains stock target with Buy rating on clinical trial - Investing.com UK

Nov 11, 2024

Nov 08, 2024

Stifel maintains Buy on Pliant Therapeutics, target at $32 By Investing.com - Investing.com UK

Nov 08, 2024

HC Wainwright Reiterates "Buy" Rating for Pliant Therapeutics (NASDAQ:PLRX) - MarketBeat

Nov 08, 2024

Nov 07, 2024

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - The Manila Times

Nov 07, 2024

Pliant Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024

Possible Bearish Signals With Pliant Therapeutics Insiders Disposing Stock - Simply Wall St

Nov 07, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by Harbor Capital Advisors Inc. - MarketBeat

Nov 07, 2024

Nov 06, 2024

Pliant Therapeutics to Participate in the Stifel Healthcare Conference - The Manila Times

Nov 06, 2024

Pliant Therapeutics to Present at Stifel 2024 Healthcare Conference | Key Leadership Insights | PLRX Stock News - StockTitan

Nov 06, 2024

Nov 03, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Nov 03, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Nov 03, 2024

Oct 21, 2024

Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 5.4%Time to Sell? - MarketBeat

Oct 21, 2024

SG Americas Securities LLC Decreases Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Oct 21, 2024

Oct 17, 2024

Pliant reports positive Phase 2a trial results for liver disease drug - Investing.com Australia

Oct 17, 2024

Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating - GlobeNewswire

Oct 17, 2024

Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024 - Yahoo Finance

Oct 17, 2024

Oct 15, 2024